Australia
# |
Name |
Net Cash Used Provided By Financing Activities |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD 243.73 M
|
June 30, 2024 | NA |
|
Australia |
||
2 |
USD 76.82 M
|
June 30, 2024 | USD 2.34 | -4.83% |
|
Australia |
|
3 |
USD 63.46 M
|
June 30, 2024 | USD 2.09 | 0.97% |
|
Australia |
|
4 |
USD 49.68 M
|
Dec. 31, 2023 | USD 6.22 | 1.04% |
|
Australia |
|
5 |
USD 40.25 M
|
June 30, 2024 | USD 1.84 | -3.30% |
|
Australia |
|
6 |
USD 6.94 M
|
Dec. 31, 2023 | USD 18.31 | -0.05% |
|
Australia |
|
7 |
USD 6.15 M
|
June 30, 2024 | USD 4.80 | 5.03% |
|
Australia |
|
8 |
USD 552.74
|
June 30, 2024 | USD 2.04 | -5.56% |
|
Australia |
|
9 |
USD 0.00
|
June 30, 2024 | USD 1.67 | 2.45% |
|
Australia |
|
10 |
USD -2.11 M
|
June 30, 2024 | USD 1.23 | 0.02% |
|
Australia |
|
11 |
USD -2.38 M
|
June 30, 2024 | USD 7.25 | -0.16% |
|
Australia |
|
12 |
USD -3.28 M
|
June 30, 2024 | USD 0.74 | 0.02% |
|
Australia |
|
13 |
USD -6.93 M
|
June 30, 2024 | USD 0.74 | 0.02% |
|
Australia |
|
14 |
USD -97.44 M
|
June 30, 2024 | USD 2.33 | 0.29% |
|
Australia |
|
15 |
USD -1.28 B
|
June 30, 2024 | USD 171.50 | 0.95% |
|
Australia |
The Clinical Trials company in Australia with the highest Net Cash Used Provided By Financing Activities is Opthea Limited (ASX: OPT.AX) at USD 243.73 M.
The Clinical Trials company in Australia with the lowest Net Cash Used Provided By Financing Activities is CSL Limited (ASX: CSL.AX) at USD -1.28 B.
The top 10 Clinical Trials companies in Australia by Net Cash Used Provided By Financing Activities are Opthea Limited, Clarity Pharmaceuticals Ltd, Immutep Limited, Anteris Technologies Ltd, Mesoblast Limited, Telix Pharmaceuticals Limited, Alterity Therapeutics Limited, Immuron Limited, Incannex Healthcare Limited and PolyNovo Limited.
The bottom 10 Clinical Trials companies in Australia by Net Cash Used Provided By Financing Activities are CSL Limited, Australian Clinical Labs Limited, Monash IVF Group Limited, Cogstate Limited, Clinuvel Pharmaceuticals Limited, PolyNovo Limited, Incannex Healthcare Limited, Immuron Limited, Alterity Therapeutics Limited and Telix Pharmaceuticals Limited.